56225-81-1

Basic information

• Product Name: 3-(4-(TRIFLUOROMETHYL)PHENOXY)-N,N-DIMETHYL-3-PHENYLPROPAN-1-AMINE
• Synonyms: N,N-DIMETHYL-GAMMA-[4-(TRIFLUOROMETHYL)PHENOXY]BENZENEPROPANAMINE;N,N-DIMETHYL-GAMMA-(4-TRIFLUOROMETHYL PHENOXY) PHENYL PROPYLAMINE;3-(4-(TRIFLUOROMETHYL)PHENOXY)-N,N-DIMETHYL-3-PHENYLPROPAN-1-AMINE;N,N-Dimethyl-γ-[4-(trifluoromethyl)phenoxy]benzenepropanamine;N,N-Dimethyl-y-[4-(trifluoromethyl)phenoxyl]benzenepropanamine
• CAS NO: 56225-81-1
• Molecular Formula: C₁₈H₂₀F₃NO
• Molecular Weight: 323.35
• Product Categories: (intermediate of fluoxetine hydrochloride)
• Mol File: 56225-81-1.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 388.078°C at 760 mmHg
• Flash Point: 188.503°C
• Appearance: /
• Density: 1.148g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.513
• CAS DataBase Reference: 3-(4-(TRIFLUOROMETHYL)PHENOXY)-N,N-DIMETHYL-3-PHENYLPROPAN-1-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-(TRIFLUOROMETHYL)PHENOXY)-N,N-DIMETHYL-3-PHENYLPROPAN-1-AMINE(56225-81-1)
• EPA Substance Registry System: 3-(4-(TRIFLUOROMETHYL)PHENOXY)-N,N-DIMETHYL-3-PHENYLPROPAN-1-AMINE(56225-81-1)

Safety Data

• Hazardous Substances Data: 56225-81-1(Hazardous Substances Data)

Usage

Description

3-(4-(TRIFLUOROMETHYL)PHENOXY)-N,N-DIMETHYL-3-PHENYLPROPAN-1-AMINE, also known as N,N-Dimethyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine, is a phenoxyphenyl diamine-based compound with histamine H3 antagonist properties and serotonin reuptake inhibitor activity. It is a complex organic molecule that has potential applications in the pharmaceutical industry due to its unique chemical structure and biological activities.

Uses

Used in Pharmaceutical Industry:
3-(4-(TRIFLUOROMETHYL)PHENOXY)-N,N-DIMETHYL-3-PHENYLPROPAN-1-AMINE is used as a histamine H3 antagonist for its ability to block the histamine H3 receptor, which plays a role in various physiological processes, including the regulation of wakefulness, appetite, and cognitive functions. Its antagonistic action on the histamine H3 receptor can potentially be utilized in the treatment of conditions such as narcolepsy, attention deficit hyperactivity disorder (ADHD), and Alzheimer's disease.
Additionally, 3-(4-(TRIFLUOROMETHYL)PHENOXY)-N,N-DIMETHYL-3-PHENYLPROPAN-1-AMINE is used as a serotonin reuptake inhibitor due to its ability to inhibit the reuptake of serotonin, a neurotransmitter involved in mood regulation, appetite, and cognitive functions. This property makes it a potential candidate for the treatment of depression, anxiety, and other mood disorders.

InChI:InChI=1/C18H20F3NO/c1-22(2)13-12-17(14-6-4-3-5-7-14)23-16-10-8-15(9-11-16)18(19,20)21/h3-11,17H,12-13H2,1-2H3

Upstream product

• 402-45-9 4-hydroxybenzotrifluoride 
• 5554-64-3 N,N-dimethyl-3-hydroxy-3-phenylpropylamine 
• 40116-79-8 (R)-(+)-3-(dimethylamino)-1-phenylpropan-1-ol 
• 1011-59-2 3-(dimethylamino)-1-phenylpropyl chloride hydrochloride 
• 124-40-3 dimethyl amine 
• 81347-68-4 1-chloro-3-phenyl-3-(4-trifluoromethylphenoxy)propane 
• 104-52-9 phenylpropyl chloride 
• 21763-00-8 1-bromo-3-chloro-1-phenylpropane 
• 98-86-2 acetophenone 
• 3506-36-3 3-dimethylaminopropiophenone 
• 79130-51-1 3-chloro-N,N-dimethyl-3-phenylpropan-1-amine 
• 50-00-0 formaldehyd 
• 64-18-6 formic acid 
• 83891-03-6 norfluoxetine 

Downstream Products

• 159216-85-0 N,N-dimethyl-N-benzyl-3-(P-trifluoromethylphenoxy)-3-phenylpropylammonium chloride 
• 57226-06-9 N-methyl-N-cyano 3-(p-trifluoromethylphenoxy)-3-phenylpropylamine 
• 204704-95-0 C₂₀H₂₂F₃NO₃ 

Relevant articles and documents

An azetidinium ion approach to 3-aryloxy-3-aryl-1-propanamines

Treatment of 3-(dimethylamino)-1-phenyl-propan-1-ol with mesyl chloride and then different phenols generates a range of N,N-dimethyl-3-aryloxy-3-aryl-1-propanamines via regiospecific opening of a proposed azetidinium ion intermediate. During the rearrangement process, there was some leakage of stereochemical integrity.

Derivatization of common antidepressant drugs increases inhibition of acid sphingomyelinase and reduces induction of phospholipidosis

In recent studies, major depressive disorder (MDD) was linked to an increase in acid sphingomyelinase (ASM) activity. Several drugs that are commonly used to treat MDD functionally inhibit the lysosomal enzyme ASM and are called functional inhibitors of ASM (FIASMAs). These drugs are classified as cationic amphiphilic drugs (CADs) that influence the catalytic activities of different lysosomal enzymes. This action results in the side effect of phospholipidosis (PLD), which describes a detrimental increase in the phospholipid content in lysosomes. FIASMAs differ only slightly in their physico-chemical properties, but their effects on ASM activity and induction of the lysosomal phospholipid content vary significantly. In this study, we systematically induced minor chemical modifications to the FIASMAs imipramine, desipramine and fluoxetine. We generated a library of 45 new CADs with slightly different log P (logarithmic partition coefficient) and pKa (logarithmic acid dissociation constant) values. The effects of the compounds on the ASM activity and lysosomal phospholipid content were assessed in cell culture assays. We identified four compounds with beneficial effects, i.e., increased ASM activity inhibition and reduced PLD induction compared with the original drugs. The compounds HT04, RH272B and RH272D outperformed the original imipramine, whereas RH281A performed better than desipramine. Thus, minor chemical variations of CADs impact lysosomal metabolism in a specific manner and can lead to antidepressant drugs with less deleterious side effects.

Pulmonary delivery for bioconjugation

Methods of and compositions for pulmonary delivery of therapeutic agents which are capable of forming covalent bonds with a site of interest or which have formed a covalent bond with a pulmonary solution protein are disclosed. Therapeutic agents useful in the invention include wound healing agents, antibiotics, anti-inflammatories, anti-oxidants, anti-proliferatives, immunosupressants, anti-infective and anti-cancer agents.